Krystexxa Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Krystexxa market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

The growth observed in the historical period can be attributed to factors such as the increasing elderly population, a rise in clinical studies, higher prevalence of chronic and refractory conditions, greater adoption of telemedicine in healthcare, and expanded coverage for biologic treatments.

Growth during the market's forecast period is driven by the rising prevalence of chronic conditions, the expanding global population, growing demand for intravenous pegloticase, higher prevalence of gout, and increasing healthcare expenditure. Key trends in the forecast period include a shift towards subcutaneous delivery, the use of artificial intelligence in clinical trials, technological advancements, the development of innovative products, and progress in pegylation technology.

The rising prevalence of gout disease is expected to drive the growth of the krystexxa market in the future. Gout is a type of arthritis caused by the accumulation of uric acid crystals in the joints, leading to inflammation, pain, and swelling. The increasing incidence of gout can be attributed to factors such as poor diet, obesity, aging, certain medications, genetic predisposition, chronic kidney disease, a sedentary lifestyle, and comorbidities such as hypertension and diabetes. Krystexxa (pegloticase) helps gout patients by lowering uric acid levels in the blood, specifically targeting chronic gout that is resistant to traditional treatments. This action helps reduce the frequency and severity of gout flare-ups, providing relief from the painful symptoms. For example, in June 2024, the Australian Institute of Health and Welfare reported that in 2022, gout was responsible for 573 deaths in Australia, equating to 2.2 deaths per 100,000 people. This accounted for 0.3% of total deaths and 5.5% of deaths related to musculoskeletal conditions. Therefore, the increasing incidence of gout disease is driving the growth of the krystexxa market.

A significant trend in the krystexxa market is the focus on combination therapy, which aims to enhance efficacy, reduce the development of anti-drug antibodies, and improve patient outcomes in the treatment of uncontrolled gout. Combination therapy involves using two or more treatments together to enhance effectiveness and improve patient outcomes, often targeting different aspects of a condition. For instance, in July 2022, Horizon Therapeutics, an Ireland-based biotechnology company, received a supplemental biologics license application (sBLA) approval from the U.S. Food and Drug Administration (FDA), expanding the labeling of Krystexxa (pegloticase) to include its co-administration with methotrexate for treating adult patients with uncontrolled chronic gout. This combination therapy improves efficacy by reducing the development of anti-drug antibodies and enhancing patient response.

In October 2023, Amgen Inc., a U.S.-based biopharmaceutical company, acquired Horizon Therapeutics Plc for $27.8 billion. This acquisition strengthens Amgen's position in the rare disease and inflammation market, with Horizon Therapeutics specializing in providing krystexxa.

The key company operating in the krystexxa market is Amgen Inc.

North America was the largest region in the krystexxa market in 2024. North America is expected to be the fastest-growing region in the forecast period. The regions covered in krystexxa report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the krystexxa market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Krystexxa (pegloticase) is a medication used to treat chronic gout in patients who do not respond to conventional treatments. It is administered as an intravenous infusion and works by breaking down uric acid, lowering uric acid levels in the body, which helps prevent gout attacks and related complications.

The primary formulations in the krystexxa market are injectable forms, including a lyophilized powder and ready-to-use solutions. The injectable formulation, which is a lyophilized powder, is a freeze-dried version of the drug that is reconstituted with a diluent before administration. Key indications for krystexxa include the treatment of chronic gout, management of hyperuricemia in gout patients, and the treatment of refractory gout. The patient demographics include adults, elderly patients, and those with comorbid conditions. Distribution channels include direct sales, wholesalers and distributors, retail pharmacies, and online pharmacies, while end users consist of hospitals, specialty clinics, rheumatology practices, and home healthcare providers.

The krystexxa market research report is one of a series of new reports that provides krystexxa market statistics, including krystexxa industry global market size, regional shares, competitors with a krystexxa market share, detailed krystexxa market segments, market trends, and opportunities, and any further data you may need to thrive in the krystexxa industry. This krystexxa market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The krystexxa market consists of sales of pegloticase and infusion kits sales. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.